Logo image of ADOC.PA

ADOCIA SAS (ADOC.PA) Stock Fundamental Analysis

Europe - EPA:ADOC - FR0011184241 - Common Stock

8.38 EUR
+0.78 (+10.26%)
Last: 9/22/2025, 7:00:00 PM
Fundamental Rating

2

Taking everything into account, ADOC scores 2 out of 10 in our fundamental rating. ADOC was compared to 77 industry peers in the Biotechnology industry. ADOC has a bad profitability rating. Also its financial health evaluation is rather negative. ADOC is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ADOC has reported negative net income.
In the past year ADOC has reported a negative cash flow from operations.
ADOC had negative earnings in each of the past 5 years.
ADOC had a negative operating cash flow in each of the past 5 years.
ADOC.PA Yearly Net Income VS EBIT VS OCF VS FCFADOC.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M -20M

1.2 Ratios

With a Return On Assets value of -34.50%, ADOC perfoms like the industry average, outperforming 42.86% of the companies in the same industry.
Industry RankSector Rank
ROA -34.5%
ROE N/A
ROIC N/A
ROA(3y)-47.28%
ROA(5y)-53.84%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ADOC.PA Yearly ROA, ROE, ROICADOC.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200

1.3 Margins

With an excellent Gross Margin value of 87.98%, ADOC belongs to the best of the industry, outperforming 81.82% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for ADOC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 87.98%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADOC.PA Yearly Profit, Operating, Gross MarginsADOC.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K -2.5K

More info and screens

2

2. Health

2.1 Basic Checks

ADOC does not have a ROIC to compare to the WACC, probably because it is not profitable.
ADOC has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ADOC has more shares outstanding
Compared to 1 year ago, ADOC has an improved debt to assets ratio.
ADOC.PA Yearly Shares OutstandingADOC.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
ADOC.PA Yearly Total Debt VS Total AssetsADOC.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

ADOC has an Altman-Z score of 0.49. This is a bad value and indicates that ADOC is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.49, ADOC is in line with its industry, outperforming 49.35% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 0.49
ROIC/WACCN/A
WACC7.73%
ADOC.PA Yearly LT Debt VS Equity VS FCFADOC.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 1.08 indicates that ADOC should not have too much problems paying its short term obligations.
ADOC has a worse Current ratio (1.08) than 72.73% of its industry peers.
ADOC has a Quick Ratio of 1.07. This is a normal value and indicates that ADOC is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of ADOC (1.07) is worse than 70.13% of its industry peers.
Industry RankSector Rank
Current Ratio 1.08
Quick Ratio 1.07
ADOC.PA Yearly Current Assets VS Current LiabilitesADOC.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 66.43% over the past year.
ADOC shows a strong growth in Revenue. In the last year, the Revenue has grown by 333.49%.
ADOC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 34.18% yearly.
EPS 1Y (TTM)66.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.28%
Revenue 1Y (TTM)333.49%
Revenue growth 3Y86.19%
Revenue growth 5Y34.18%
Sales Q2Q%1682.03%

3.2 Future

The Earnings Per Share is expected to decrease by -35.05% on average over the next years. This is quite bad
The Revenue is expected to decrease by -18.38% on average over the next years. This is quite bad
EPS Next Y-69.76%
EPS Next 2Y-63.12%
EPS Next 3Y-27.26%
EPS Next 5Y-35.05%
Revenue Next Year-52.48%
Revenue Next 2Y-30.63%
Revenue Next 3Y-42.95%
Revenue Next 5Y-18.38%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ADOC.PA Yearly Revenue VS EstimatesADOC.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 50M 100M 150M
ADOC.PA Yearly EPS VS EstimatesADOC.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4 6

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

ADOC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 4.59, the valuation of ADOC can be described as very cheap.
Based on the Price/Forward Earnings ratio, ADOC is valued cheaply inside the industry as 98.70% of the companies are valued more expensively.
ADOC is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.87, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 4.59
ADOC.PA Price Earnings VS Forward Price EarningsADOC.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADOC.PA Per share dataADOC.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

A cheap valuation may be justified as ADOC's earnings are expected to decrease with -27.26% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-63.12%
EPS Next 3Y-27.26%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ADOC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADOCIA SAS

EPA:ADOC (9/22/2025, 7:00:00 PM)

8.38

+0.78 (+10.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14
Earnings (Next)09-25 2025-09-25
Inst Owners14.87%
Inst Owner ChangeN/A
Ins Owners9.82%
Ins Owner ChangeN/A
Market Cap153.19M
Analysts85
Price Target14.28 (70.41%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)40%
PT rev (3m)53.01%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-58.94%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)1.38%
Revenue NY rev (3m)-41.51%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 4.59
P/S 16.44
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.65
EYN/A
EPS(NY)1.83
Fwd EY21.79%
FCF(TTM)-0.87
FCFYN/A
OCF(TTM)-0.85
OCFYN/A
SpS0.51
BVpS-0.17
TBVpS-0.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -34.5%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 87.98%
FCFM N/A
ROA(3y)-47.28%
ROA(5y)-53.84%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 35.02%
Cap/Sales 2.46%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.08
Quick Ratio 1.07
Altman-Z 0.49
F-Score5
WACC7.73%
ROIC/WACCN/A
Cap/Depr(3y)32.19%
Cap/Depr(5y)28.97%
Cap/Sales(3y)3.68%
Cap/Sales(5y)12.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)66.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.28%
EPS Next Y-69.76%
EPS Next 2Y-63.12%
EPS Next 3Y-27.26%
EPS Next 5Y-35.05%
Revenue 1Y (TTM)333.49%
Revenue growth 3Y86.19%
Revenue growth 5Y34.18%
Sales Q2Q%1682.03%
Revenue Next Year-52.48%
Revenue Next 2Y-30.63%
Revenue Next 3Y-42.95%
Revenue Next 5Y-18.38%
EBIT growth 1Y48.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-22.86%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-210.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-215.33%
OCF growth 3YN/A
OCF growth 5YN/A